PLAT and immune system disorder: Of the 373 patients with acute ischemic stroke who were treated intravenously with recombinant tissue plasminogen activator during our enrollment period, we excluded 19 with no baseline MHR, four with no follow-up computed tomography, eight with otherwise incomplete medical records, and two with severe infection or immune disorder.